Skip to main content
VOLITIONRX LTD logo

VOLITIONRX LTD — Investor Relations & Filings

Ticker · VNRX ISIN · US9286611077 US Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2026-06-09 Capital/Financing Update
Country US United States of America
Listing US VNRX

About VOLITIONRX LTD

https://volition.com/

VolitionRx Ltd. is an epigenetics company that develops blood tests for the early diagnosis and monitoring of life-altering diseases in both humans and animals. The company's core technology is its proprietary Nu.Q® platform, which is based on the science of Nucleosomics. This platform detects and quantifies characteristic changes in circulating nucleosomes, which are fragments of chromatin released from cells. These nucleosomes act as biomarkers for various conditions, enabling the development of simple, cost-effective, and non-invasive tests. VolitionRx's primary focus is on applications for detecting and monitoring cancers and sepsis, with the goal of improving patient outcomes by making diagnostics more accessible.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 92% confidence The document is a Form 8-K (“Current Report”) filed under the Securities Exchange Act. It details the Company’s entry into a securities purchase agreement, the sale of common stock and warrants, net proceeds, placement agency agreement, and related financing terms. This is a clear announcement of a financing activity (capital raising and capital structure change), matching the Capital/Financing Update category (CAP).
2026-06-09 English
424B5
Capital/Financing Update Classification · 85% confidence The document is a Form 424B5 prospectus supplement and base prospectus filed under Rule 424(b)(5) in connection with a registered offering of common stock and warrants. It provides detailed terms of a new equity and warrant issuance, pricing, placement agent fees, use of proceeds and related financing details. This clearly constitutes a capital raising/financing activity rather than an annual report, earnings release, or management discussion, matching our definition for Capital/Financing Update (CAP).
2026-06-09 English
424B5
Capital/Financing Update Classification · 89% confidence The document is a preliminary prospectus supplement filed under Rule 424(b)(5) for an equity offering (shares, pre-funded warrants, and common stock purchase warrants). It is clearly a capital-raising/fundraising document, detailing the terms of an offering of new securities. This aligns with the Capital/Financing Update (CAP) category, which covers updates on company fundraising and financing activities.
2026-06-05 English
DEF 14A
Proxy Solicitation & Information Statement
2026-06-02 English
FORM 8-K
Capital/Financing Update Classification · 88% confidence The document is a Form 8-K “Item 1.01 Entry into a Material Definitive Agreement” describing the issuance and amendment (waiver and consent) of senior secured convertible promissory notes and related covenant actions. This is a financing-related event updating the company’s capital structure rather than an earnings release or annual/quarterly report. Therefore, it falls under the Capital/Financing Update category.
2026-05-22 English
FORM 8-K
Board/Management Information Classification · 88% confidence The document is a Form 8-K Current Report (Item 5.02) filed by VolitionRx Limited announcing the departure of a board director (Mickie Henshall) and changes to the board size. This is an announcement of changes to the company’s board of directors, matching the Board/Management Information category.
2026-05-15 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.